Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sitagliptin mitigates olanzapine-related metabolic abnormalities to some extent

Key clinical point: Sitagliptin may effectively reduce some metabolic abnormalities associated with olanzapine in patients with the schizophrenia.

Major finding: At 12 weeks, there was a significant reduction in total cholesterol (P = .001) and glycated hemoglobin (P = .000) with olanzapine plus sitagliptin vs. olanzapine plus placebo. There were no significant differences in body mass index and waist circumference between the two groups.

Study details: A 12-week double-blind placebo-controlled clinical trial involving 61 patients who were randomly assigned to receive olanzapine plus sitagliptin (n = 30) or olanzapine plus placebo (n = 31).

Disclosures: The study was funded by the Shiraz University of Medical Sciences. The authors declared no conflicts of interest.

Citation:

Moghimi-Sarani E et al. J Clin Psychopharmacol. 2020 Jul 21. doi: 10.1097/JCP.0000000000001259.